GoDaddy sacks hundreds despite business growth - San Francisco News
by Maria Thomas
Updated Jun 28, 2020
Most of the employees who have been asked to depart are working in the company's social media sales team in Austin, Texas.
In a statement on June 24, the company said it saw soft customer demand for certain higher-priced, do-it-for-you services such as GoDaddy Social, and reduced effectiveness of outbound calling to customers.
GoDaddy's decision to implement a restructuring, affecting approximately 814 employees, only demonstrates that the Covid-19 challenges are hardly sparing anyone – not even those who have seen growth in their overall business.
However, over 40 per cent of these 814 employees affected by the restructuring are being offered alternate roles in the company.
"Our facilities in Austin carry unique costs and complexities, so we will be closing both Austin locations," GoDaddy CEO Aman Bhutani said in a letter to employees as he announced that 331 members of GoDaddy Social sales team in Austin will be departing the company.
Bhutani, however, stressed that the "core of the GoDaddy business continues to be strong and we will look to hire team members back as we continue to grow."
The company's management now expects second quarter revenue to exceed previously issued guidance of $790 million by approximately one per cent.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report